Tevogen Bio Holdings Inc. TVGN R2K

Healthcare · Biotechnology · United States

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Market & Price

Market Cap

$33.12M

Current Price

$7.91

High / Low (52W)

$71.50 / $4.29

Beta

0.10

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$-4.24

Price to Book

-1.87

P/S

EV/EBITDA

-2.41

Dividend Yield

Profitability & Returns

ROCE

ROE

ROA

Profit Margin

0.00%

Op Margin

0.00%

EPS (Latest Qtr)

$-1.61

EPS (TTM)

$-6.44

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

0.12

Current Ratio

0.29

Debt

$9.47M

Total Assets

$4.38M

Current Assets

$1.54M

Working Capital

$-5.53M

Ownership

Promoter Holding

74.41%

Chg in Prom Hold

FII / Inst Holding

3.62%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$50.70M

Total Revenue (TTM)

EBITDA

$-21.00M

Free Cash Flow

$-3.17M

Operating Cash Flow

$-11.75M

Shares Outstanding

4.19M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

-232.01%

Revenue (YoY)

Earnings (YoY)

PROS

No notable strengths flagged.

CONS

Earnings shrank at -232.0% CAGR over 5 years.
Trading 88.9% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	TVGN Tevogen Bio Holdings Inc. R2K	7.91	-	$33.12M	-	-	-	-	-232.01%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	10.36M	5.44M	5.73M	4.61M	5.40M
Operating Income	-	-	-	-	-	-2.32M	-2.18M	-2.33M	-29.52M	-8.60M	-	-	-10.36M	-5.44M	-5.73M	-4.61M	-5.40M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-10.24M	-5.42M	-5.37M	-4.52M	-5.32M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	15.80K	24.57K	-	62.34K	70.67K	71.17K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-10.37M	-5.50M	-5.73M	-4.68M	-5.45M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-11.30K	-115	-25.99K	207.00K	1.61M	-30.76M	-22.18M	-3.90M	11.26M	-9.66M	-	-	-10.37M	-5.50M	-5.73M	-4.68M	-5.45M
Diluted EPS	-	-	0.00	-	-	-0.26	-0.18	-0.03	-0.26	-0.04	-1.50	-	-3.25	-1.50	-1.50	-	-1.61
R&D Expense	-	-	-	-	-	1.35M	1.03M	1.12M	20.81M	4.12M	3.26M	-	3.20M	2.70M	3.11M	-	3.13M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	0	0	0	0
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expenses	-	953.08K	8.84M	53.56M	26.14M
Operating Income	-	-953.08K	-8.84M	-53.56M	-26.14M
EBITDA	-	4.41M	-58.89M	-13.14M	-25.57M
Interest Expense	-	0	1.21M	184.04K	195.62K
Pretax Income	-	4.41M	-60.48M	-13.73M	-26.28M
Tax Provision	-	-	-	-	-
Net Income	-	4.41M	-60.48M	-13.73M	-26.28M
Diluted EPS	-	1.84	-19.12	-3.50	-8.08
R&D Expense	-	-	4.40M	31.03M	11.11M

Compounded Sales Growth

5 Years:	-
1 Year:	-

Compounded Profit Growth

5 Years:	-232.01%
1 Year:	-

Stock Price Performance

1 Year:	-87.74%
6 Months:	-63.96%
3 Months:	-40.08%
1 Month:	+23.21%

Balance Sheet (Annual)

Figures in USD.

Metric	Apr 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	352.85M	357.14M	5.51M	3.46M	4.38M
Current Assets	-	-	274.36K	1.72M	2.36M	1.54M
Cash & Equivalents	-	344.58K	129.19K	1.05M	1.28M	552.37K
Inventory	-	-	-	-	-	-
Receivables	-	-	0	0	158.82K	158.82K
Total Liabilities	-	15.18M	15.06M	99.93M	10.14M	12.62M
Current Liabilities	-	59.38K	350.45K	85.48M	9.04M	7.07M
Long Term Debt	-	-	39.30M	14.22M	1.00M	4.40M
Total Debt	-	-	40.01M	95.42M	2.89M	7.50M
Total Equity	0	-14.23M	342.08M	-94.43M	-6.67M	-8.23M
Shares Outstanding	-	-	3.16M	3.31M	3.56M	4.02M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-215.40K	-8.17M	-12.00M	-12.33M
Investing Cash Flow	-	0	-133.00K	0	-64.44K
Financing Cash Flow	-	0	3.87M	12.23M	11.66M
Capital Expenditure	-109.73K	-479.04K	-133.00K	-	-64.44K
Free Cash Flow	-	-215.40K	-8.30M	-12.00M	-12.39M
Net Change in Cash	-	-215.40K	-4.43M	230.60K	-730.62K
Share Buybacks	-	-	342.98M	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-
Operating Margin %	-	-	-	-	-
Net Margin %	-	-	-	-	-
ROE %	-	1.3%	64.0%	205.7%	319.1%
ROCE %	-	-0.3%	11.1%	959.8%	973.4%

Shareholding Pattern

Insiders

74.41%

Institutions

3.62%

Public Float

14.14%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Vanguard Capital Management LLC	0.79%	33.25K	$262.99K
2	Blackrock Inc.	0.58%	24.39K	$192.96K
3	Morgan Stanley	0.41%	17.33K	$137.11K
4	Geode Capital Management, LLC	0.38%	15.73K	$124.45K
5	Deutsche Bank AG	0.37%	15.32K	$121.21K
6	FMR, LLC	0.24%	10.16K	$80.34K
7	Russell Investments Group, Ltd.	0.14%	5.81K	$45.92K
8	Vanguard Portfolio Management LLC	0.11%	4.53K	$35.79K
9	UBS Group AG	0.09%	3.57K	$28.21K
10	Vanguard Fiduciary Trust Co	0.03%	1.37K	$10.82K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TVGN

No recent headlines available.

TVGN · Healthcare